Entera Bio Stock

Entera Bio Dividend

Dividend of Entera Bio (ENTX) as of Aug 2, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Entera Bio 2026 pay?

According to the latest status from August 2026, Entera Bio paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Entera Bio price of 2.99 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Entera Bio Dividends

PaydateDividend

Is the Entera Bio Dividend Safe?

Entera Bio has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Entera Bio's Dividend Distributions

Entera Bio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Entera Bio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Entera Bio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Entera Bio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Entera Bio paid dividends every year for the past 0 years.

Dividend calendar 2026
Access this data via the Eulerpool API
Get Free API Key

All Key Metrics — Entera Bio